Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493186 | 0.87 | PSEN1 (0.45) | ALDH1A1MEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL494049 | 0.85 | MEN1 (0.35) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL493720 | 0.84 | RAB9A (0.46) | ALDH1A1MEN1KMT2APOLBRAB9A | |
| SCHEMBL492880 | 0.83 | KMT2A (0.41) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL492898 | 0.82 | FKBP1A (0.42) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL493738 | 0.81 | RAB9A (0.43) | MEN1KMT2APOLBRAB9AGAA | |
| SCHEMBL493108 | 0.81 | GAA (0.42) | ATMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL493222 | 0.80 | SMN1; SMN2 (0.44) | ATMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL492796 | 0.79 | HTR7 (0.39) | ATMALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL493111 | 0.78 | MEN1 (0.39) | ATMMEN1KMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | HSD11B1 2834/4885ATM 1904/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.